News FDA sets new decision date for Ipsen’s FOP therapy US agency sets 23rd August deadline for palovarotene review as Ipsen files more clinical data.
News Ipsen adds Blueprint's FOP rare disease drug to pipeline for... Ipsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a licence to develop and market a drug for the rare disease fibrodysplasia ossifican
News Could Daiichi Sankyo have another ADC winner in cancer? New data point to impressive efficacy in advanced EGFR-mutated non-small cell lung cancer.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK
